Skip to main content
main-content

Nephropathy

22-09-2022 | EASD 2022 | Conference coverage | News

Microalbuminuria in pregnancy forecasts adverse outcomes

Women with type 1 diabetes who have microalbuminuria at the time of pregnancy have an increased risk for adverse pregnancy outcomes in the short term and for diabetes complications in the long term, shows research.

09-09-2022 | COVID-19 | News

Microvascular complications linked to COVID-19 mortality risk in people with type 2 diabetes

Study findings suggest that the presence of microvascular complications is associated with increased risk for all-cause mortality in people with type 2 diabetes hospitalized for COVID-19.

18-08-2022 | Finerenone | News

Finerenone benefits independent of SGLT2 inhibitor use

Pooled analysis of FIDELIO-DKD and FIGARO-DKD suggests that people with type 2 diabetes and chronic kidney disease benefit from finerenone irrespective of whether they are also using an SGLT2 inhibitor.

07-07-2022 | Risk factors | News

Smoking ‘important risk factor’ for albuminuria in people with prediabetes

Smoking is associated with an increased risk for albuminuria in both people with prediabetes and those with diabetes, but quitting may not immediately circumvent this risk, researchers report.

21-06-2022 | Nephropathy | News

Real-world data confirm SGLT2 inhibitor renoprotection in type 2 diabetes

People with type 2 diabetes have a lower risk for chronic kidney disease progression and death when using SGLT2 inhibitors than when given DPP-4 inhibitors, real-world study data show.

08-06-2022 | ADA 2022 | Conference coverage | News

CKD and type 2 diabetes combined conveys greatest vascular risk in people with CVD

Individuals with cardiovascular disease who also have both chronic kidney disease and type 2 diabetes have a high risk for major cardiovascular events, shows research. 

Guidelines

07-06-2022 | ADA 2022 | Conference coverage | News

​​​​​​​ADA/KDIGO consensus: ‘Speaking the same language’ on CKD management

The ADA and KDIGO have produced a consensus statement on treating chronic kidney disease in people with diabetes.

05-06-2022 | ADA 2022 | Conference coverage | News

Renal benefits of tirzepatide revealed

Tirzepatide may have a renoprotective effect in people with type 2 diabetes and high vascular risk, shows a prespecified analysis of SURPASS-4.